IMAC HOLDINGS INC. - COMMON STOCK

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

24 2 2025 08:15:00 提供 Nasdaq GlobeNewswire

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

19 2 2025 09:15:00 提供 Nasdaq GlobeNewswire

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

10 2 2025 09:15:00 提供 Nasdaq GlobeNewswire

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

27 1 2025 16:10:00 提供 Nasdaq GlobeNewswire

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

22 11 2024 17:15:00 提供 Nasdaq GlobeNewswire

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

14 11 2024 09:10:00 提供 Nasdaq GlobeNewswire

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

19 9 2024 10:00:00 提供 Nasdaq GlobeNewswire

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

23 8 2024 17:20:00 提供 Nasdaq GlobeNewswire

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

11 7 2024 09:21:00 提供 Nasdaq GlobeNewswire

IMAC Holdings Announces Leadership Succession

24 5 2024 09:00:00 提供 Nasdaq GlobeNewswire

IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

07 5 2024 08:30:00 提供 Nasdaq GlobeNewswire